vaccines-gynecologic-oncology-2018-posters

Page 79

Journal of Clinical Immunology and Allergy

ISSN: 2471-304X

E u r o p e a n C o n g r e s s o n

Vaccines & Vaccination

and Gynecologic Oncology

Vaccines & Vaccination and Gynecologic Oncology 2018

O c t o b e r 2 6 - 2 7 , 2 0 1 8

B u d a p e s t , H u n g a r y

he vaccine segment is anticipated to be one of the fastest growing one of the healthcare industry and several leading firms have

stepped up vaccine investments in recent years. Unlike therapeutic agents, vaccines are administered to healthy individuals only

once or very infrequently during a life time. Vaccines generate well-documented positive externalities, yet their poor awareness and

acceptability among vaccine end-users may contribute to resurgence of transmissible diseases and consequently trigger governmen-

tal interventions such as mandating vaccination. In addition to technical and clinical development per the highest quality standards,

bringing new vaccines to market requires carefully orchestrated programs targeting the multiple types of stakeholders along the entire

value chain and addressing their respective purchasing behavioural drivers. Against a backdrop of anti-vaccination buzz and vaccine

fatigue, successful global launch and sustainable usage of a vaccine requires the development of a multi-pronged strategy addressing

all aspects in relation to acceptability (e.g. the motivation to immunize despite the quasi-disappearance of the disease), accessibility

(e.g. supply chain services), availability (e.g. mechanisms ensuring reliability of supply) and affordability (e.g. tiered pricing policy tak-

ing country differences in per capita income into account). Leveraging novel technological advances can positively influence the ability

to activate these levers successfully.

Successfully activating positive behaviors of the

stakeholders involved in vaccine purchasing and

usage through technological advances

Pierre A Morgon

1, 2

MRGN Advisors, Switzerland

Virometix A, Switzerland

Journal of Clinical Immunology and Allergy, Volume: 4

DOI: 10.21767/2471-304X-C2-006

Euro Vaccines 2018